Perrigo Co. Plc (PRGO)
15.75
-0.03
(-0.19%)
USD |
NYSE |
Nov 02, 16:00
15.78
+0.03
(+0.19%)
Pre-Market: 20:00
Perrigo Enterprise Value : 5.244B for Nov. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 02, 2026 | 5.244B |
| October 30, 2026 | 5.248B |
| October 29, 2026 | 5.264B |
| October 28, 2026 | 5.267B |
| October 27, 2026 | 5.281B |
| October 26, 2026 | 5.253B |
| October 23, 2026 | 5.273B |
| October 22, 2026 | 5.330B |
| October 21, 2026 | 5.266B |
| October 20, 2026 | 5.302B |
| October 19, 2026 | 5.291B |
| October 16, 2026 | 5.366B |
| October 15, 2026 | 5.345B |
| October 14, 2026 | 5.271B |
| October 13, 2026 | 5.191B |
| October 12, 2026 | 5.202B |
| October 09, 2026 | 5.148B |
| October 08, 2026 | 5.070B |
| October 07, 2026 | 5.077B |
| October 06, 2026 | 5.001B |
| October 05, 2026 | 5.062B |
| October 02, 2026 | 5.037B |
| October 01, 2026 | 5.004B |
| September 30, 2026 | 5.106B |
| September 29, 2026 | 5.140B |
| Date | Value |
|---|---|
| September 28, 2026 | 5.153B |
| September 25, 2026 | 5.198B |
| September 24, 2026 | 5.095B |
| September 23, 2026 | 4.979B |
| September 22, 2026 | 5.044B |
| September 21, 2026 | 5.019B |
| September 18, 2026 | 4.940B |
| September 17, 2026 | 4.929B |
| September 16, 2026 | 4.937B |
| September 15, 2026 | 4.940B |
| September 14, 2026 | 4.952B |
| September 11, 2026 | 4.954B |
| September 10, 2026 | 4.944B |
| September 09, 2026 | 5.048B |
| September 08, 2026 | 5.081B |
| September 04, 2026 | 5.128B |
| September 03, 2026 | 5.038B |
| September 02, 2026 | 5.069B |
| September 01, 2026 | 5.060B |
| August 31, 2026 | 5.090B |
| August 28, 2026 | 5.067B |
| August 27, 2026 | 5.052B |
| August 26, 2026 | 5.106B |
| August 25, 2026 | 5.067B |
| August 24, 2026 | 5.038B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Eli Lilly & Co. | 1.373T |
| Merck & Co., Inc. | 413.02B |
| ANI Pharmaceuticals, Inc. | 1.858B |
| Corcept Therapeutics, Inc. | 8.385B |
| Veru, Inc. | 13.72M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 88.50M |
| Revenue (Quarterly) | 1.023B |
| Total Expenses (Quarterly) | 934.30M |
| EPS Diluted (Quarterly) | 0.5337 |
| Gross Profit Margin (Quarterly) | 30.73% |
| Profit Margin (Quarterly) | 8.65% |
| Earnings Yield | -79.43% |
| Operating Earnings Yield | 12.16% |
| Normalized Earnings Yield | -21.84 |